Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conversion.

Ronald C Petersen1

  • 1Department of Neurology and the Mayo Alzheimer Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. peter8@mayo.edu

Neurology
|November 15, 2006
PubMed
Summary
This summary is machine-generated.

Assessing treatment efficacy requires understanding transitions between cognitive states, like normal to mild cognitive impairment (MCI) or MCI to Alzheimer

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Acta neuropathologica·2017
Same author

Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).

Acta neuropathologica·2017
Same author

Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.

Alzheimer's & dementia (Amsterdam, Netherlands)·2017
Same author

Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE ε4 Genotype.

JAMA neurology·2017
Same author

Duration and Pathologic Correlates of Lewy Body Disease.

JAMA neurology·2017
Same author

<i>ABCA7</i> loss-of-function variants, expression, and neurologic disease risk.

Neurology. Genetics·2017
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Clinical Trials
  • Cognitive Science

Background:

  • Evaluating treatment effectiveness in clinical trials is complex.
  • Assessing endpoints like cognitive state transitions presents challenges.

Purpose of the Study:

  • To address the challenge of assessing endpoint conversion in treatment trials.
  • To explore criteria development for evaluating cognitive state transitions.

Main Methods:

  • Review of current methodologies for endpoint assessment.
  • Analysis of cognitive state transitions in clinical trial contexts.

Main Results:

  • Endpoint assessment in trials necessitates clear definitions for cognitive transitions.
  • Developing criteria for normal to mild cognitive impairment (MCI) and MCI to Alzheimer's disease (AD) progression is crucial.

Conclusions:

  • Standardized criteria are needed to accurately measure treatment efficacy.
  • Further research into intermediate cognitive states will refine assessment methods.